Bio Usawa Biotechnology and Bioeq AG Partner to Expand Access to Vision-Saving Treatments Across Sub-Saharan Africa 

Shots: 

• Bio Usawa Biotechnology and Bioeq AG entered into an agreement to make ranibizumab biosimilar for serious retinal diseases, accessible to millions in Sub-Saharan Africa  

• The partnership gives Bio Usawa exclusive rights to register and market Bioeq’s ranibizumab biosimilar, BioUcenta, advancing access to essential biologics in Sub-Saharan Africa  

• BioUcenta, an intravitreal injection, blocks abnormal retinal blood vessel growth and fluid leakage—major causes of vision loss. Approved in Europe and the US, it will now be registered and distributed in Sub-Saharan Africa by Bio Usawa

Ref: GlobeNewsWire | Image: Bio Usawa Biotechnology and Bioeq AG | Press Release

Related News:- Fresenius kabi Secures the CHMP’s Positive Opinion for Bomyntra & Conexxence (Biosimilar, Prolia and Xgeva)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com